A182400 Stock Overview
NKMAX CO., Ltd. manufactures and sells biological products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
NKMAX CO., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,020.00 |
| 52 Week High | ₩8,205.00 |
| 52 Week Low | ₩1,550.00 |
| Beta | 1.1 |
| 1 Month Change | 0% |
| 3 Month Change | -40.85% |
| 1 Year Change | -63.83% |
| 3 Year Change | -75.14% |
| 5 Year Change | -72.79% |
| Change since IPO | -68.68% |
Recent News & Updates
Shareholder Returns
| A182400 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0% | 4.1% | 0.5% |
| 1Y | -63.8% | 6.6% | 4.7% |
Return vs Industry: A182400 underperformed the KR Biotechs industry which returned 0.7% over the past year.
Return vs Market: A182400 underperformed the KR Market which returned 1.2% over the past year.
Price Volatility
| A182400 volatility | |
|---|---|
| A182400 Average Weekly Movement | 20.8% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A182400's share price has been volatile over the past 3 months.
Volatility Over Time: A182400's weekly volatility has increased from 13% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 134 | Sangwoo Park | www.nkmax.com |
NKMAX CO., Ltd. manufactures and sells biological products in South Korea. The company offers anti-cancer immunotherapy treatment that activates the immune cells in body to kill the cancer cells; natural killer cell activity test for cancer patients; NK VUE Kit, an NK cell activity test that quantitatively measures IFN-gamma released from activated NK cells with small amount of blood; and NK365, a proprietary blend of vitamins, minerals, and agaricus mushroom extract for immune system. It also provides recombinant proteins and monoclonal antibodies; and NK PUPPY, a test that measures dog’s immunity.
NKMAX CO., Ltd. Fundamentals Summary
| A182400 fundamental statistics | |
|---|---|
| Market cap | ₩172.74b |
| Earnings (TTM) | ₩5.26b |
| Revenue (TTM) | ₩10.77b |
32.8x
P/E Ratio16.0x
P/S RatioIs A182400 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A182400 income statement (TTM) | |
|---|---|
| Revenue | ₩10.77b |
| Cost of Revenue | ₩3.52b |
| Gross Profit | ₩7.25b |
| Other Expenses | ₩1.99b |
| Earnings | ₩5.26b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 61.52 |
| Gross Margin | 67.31% |
| Net Profit Margin | 48.85% |
| Debt/Equity Ratio | 44.3% |
How did A182400 perform over the long term?
See historical performance and comparison